
W. Kimryn (Kim) Rathmell, M.D., Ph.D.
- Hugh Jackson Morgan Chair in Medicine
- Chair, Department of Medicine
- Physician-in-Chief, Vanderbilt University Medical Center
- Professor of Biochemistry
- Professor of Biochemistry
W. Kimryn (Kim) Rathmell, M.D., Ph.D.
- Hugh Jackson Morgan Chair in Medicine
- Chair, Department of Medicine
- Physician-in-Chief, Vanderbilt University Medical Center
- Professor of Biochemistry
- Professor of Biochemistry
kimryn.rathmell@vumc.org
2220 Pierce Ave
Nashville, TN 37232-6307
Research Program
Departments/Affiliations
Provider Information
Profile
Education
- M.D., Stanford University, Stanford, California (1998)
- Ph.D., Stanford University, Stanford, California (1996)
- B.A., University of Northern Iowa, Cedar Falls, Iowa (1991)
- B.S., University of Northern Iowa, Cedar Falls, Iowa (1991)
Research Emphasis
Renal cell carcinoma
Research Description
As the Chair of the Department of Medicine, I am invested in creating a basic, translational, and clinical program that supports each of our cancer programs.
As a genitourinary oncologist, I focus on renal cell carcinoma. This cancer affects over 70,000 new patients annually in the US. We are interested in understanding all factors intrinsic and extrinsic to the cancer cell that influence tumor growth. Therefore, our research takes a broad approach using genetic, molecular, and cell biology techniques to study tumor-initiating events and events that promote the development of invasive or metastatic features using in vitro, animal, and human systems. This translational research, all geared toward enhancing our understanding of the genetics and molecular biology of hypoxia-driven cancers, is folded into a clinical research program focused on hereditary kidney cancer syndromes at the Vanderbilt University Medical Center and Vanderbilt Ingram Cancer Center.
Publications
- Haake SM, Plosa EJ, Kropski JA, Venton LA, Reddy A, Bock F, Chang BT, Luna AJ, Nabukhotna K, Xu ZQ, Prather RA, Lee S, Tanjore H, Polosukhin VV, Viquez OM, Jones A, Luo W, Wilson MH, Rathmell WK, Massion PP, Pozzi A, Blackwell TS, Zent R. Ligand-independent integrin beta1 signaling supports lung adenocarcinoma development. JCI Insight [print-electronic]. 2022 Jun 6/28/2022; PMID: 35763345, PII: 154098, DOI: 10.1172/jci.insight.154098, ISSN: 2379-3708.
- Rathmell WK, Rumble RB, Van Veldhuizen PJ, Al-Ahmadie H, Emamekhoo H, Hauke RJ, Louie AV, Milowsky MI, Molina AM, Rose TL, Siva S, Zaorsky NG, Zhang T, Qamar R, Kungel TM, Lewis B, Singer EA. Management of Metastatic Clear Cell Renal Cell Carcinoma: ASCO Guideline. J Clin Oncol [print-electronic]. 2022 Jun 6/21/2022; JCO2200868. PMID: 35728020, DOI: 10.1200/JCO.22.00868, ISSN: 1527-7755.
- Lim AR, Vincent BG, Weaver AM, Rathmell WK. Sunitinib and Axitinib increase secretion and glycolytic activity of small extracellular vesicles in renal cell carcinoma. Cancer Gene Ther [print-electronic]. 2022 Jun; 29(6): 683-96. PMID: 34088993, PMCID: PMC8642495, PII: 10.1038/s41417-021-00345-1, DOI: 10.1038/s41417-021-00345-1, ISSN: 1476-5500.
- Glass EB, Hoover AA, Bullock KK, Madden MZ, Reinfeld BI, Harris W, Parker D, Hufnagel DH, Crispens MA, Khabele D, Rathmell WK, Rathmell JC, Wilson AJ, Giorgio TD, Yull FE. Stimulating TAM-mediated anti-tumor immunity with mannose-decorated nanoparticles in ovarian cancer. BMC Cancer. 2022 May 5/6/2022; 22(1): 497. PMID: 35513776, PMCID: PMC9074180, PII: 10.1186/s12885-022-09612-2, DOI: 10.1186/s12885-022-09612-2, ISSN: 1471-2407.
- Reisman BJ, Guo H, Ramsey HE, Wright MT, Reinfeld BI, Ferrell PB, Sulikowski GA, Rathmell WK, Savona MR, Plate L, Rubinstein JL, Bachmann BO. Apoptolidin family glycomacrolides target leukemia through inhibition of ATP synthase. Nat Chem Biol [print-electronic]. 2022 Apr; 18(4): 360-7. PMID: 34857958, PMCID: PMC8967781, PII: 10.1038/s41589-021-00900-9, DOI: 10.1038/s41589-021-00900-9, ISSN: 1552-4469.
- Gallagher EJ, Rockey DC, Kontos CD, Vyas JM, Brass LF, Hu PJ, Isales CM, Ajijola OA, Rathmell WK, Conlin PR, Baiocchi RA, Kazmierczak BI, Akabas MH, Williams CS. Pearls of wisdom for aspiring physician-scientist residency applicants and program directors. JCI Insight. 2022 Mar 3/22/2022; 7(6): PMID: 35315364, PMCID: PMC8986063, PII: 158467, DOI: 10.1172/jci.insight.158467, ISSN: 2379-3708.
- Choueiri TK, Albiges L, Atkins MB, Bakouny Z, Bratslavsky G, Braun DA, Haas NB, Haanen JBAG, Hakimi AA, Jewett MAS, Jonasch E, Kaelin WG, Kapur P, Labaki C, Lewis B, McDermott DF, Pal SK, Pels K, Poteat S, Powles T, Rathmell WK, Rini BI, Signoretti S, Tannir NM, Uzzo RG, Hammers HJ. From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit. Clin Cancer Res. 2022 Mar 3/1/2022; 28(5): 831-9. PMID: 34965942, PII: 1078-0432.CCR-21-3238, DOI: 10.1158/1078-0432.CCR-21-3238, ISSN: 1557-3265.
- Reinfeld BI, Rathmell WK, Kim TK, Rathmell JC. The therapeutic implications of immunosuppressive tumor aerobic glycolysis. Cell Mol Immunol [print-electronic]. 2022 Jan; 19(1): 46-58. PMID: 34239083, PMCID: PMC8752729, PII: 10.1038/s41423-021-00727-3, DOI: 10.1038/s41423-021-00727-3, ISSN: 2042-0226.
- Gaines DK, Rathmell WK. Spatial models of tumour evolution. Nat Ecol Evol. 2022 Jan; 6(1): 26-7. PMID: 34949818, PII: 10.1038/s41559-021-01584-z, DOI: 10.1038/s41559-021-01584-z, ISSN: 2397-334X.
- Baechle JJ, Hanna DN, Sekhar KR, Rathmell JC, Rathmell WK, Baregamian N. Multiplatform computational analysis of mast cells in adrenocortical carcinoma tumor microenvironment. Surgery [print-electronic]. 2022 Jan; 171(1): 111-8. PMID: 34261605, PII: S0039-6060(21)00540-7, DOI: 10.1016/j.surg.2021.04.045, ISSN: 1532-7361.